27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Counseling and support lead to sustained benefits in reducing depressive symptoms in spouse-caregivers of Alzheimer's disease patients and should be widely available to provide effective, evidence-based intervention for family caregivers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) often represents an early form of Alzheimer disease (AD). 2 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Educational support for general practitioners should concentrate on epidemiological knowledge, disclosure of the diagnosis and management of behaviour problems in dementia. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These findings support the hypothesis that the metabolic syndrome contributes to cognitive impairment in elders, but primarily in those with high level of inflammation. 5 key findings →
Participants: 1,616 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The recent availability of longitudinal data on the possible association of different lifestyles with dementia and Alzheimer's disease (AD) allow some preliminary conclusions on this topic. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Classification resulted in 227 persons with prevalent dementia at entry into the study and 480 incident cases during follow-up. 4 key findings →
Design: cohort study Participants: 227 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Contrary to early case-control studies that suggested smoking protects against Alzheimer disease (AD), recent prospective studies have shown that elderly who smoke may be at increased risk for dementia. 4 key findings →
Design: case-control study Participants: 17,610 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In cell culture experiments, flupirtine maleate (FLU), a triaminopyridine compound, was able to protect neuronal cells from apoptotic cell death induced by prion protein fragments and beta-amyloid peptides. 4 key findings →
Participants: 13 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This review shows that occupational therapy interventions for community dwelling elderly people results in positive outcomes. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Although the effect of major depressive disorder on amygdala volume remains to be conclusively established, inclusion of the amygdala with the hippocampus appears to have decreased the likelihood of detecting volumetric differences in either structure. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Poor memory ability and small hippocampal volume measurements in magnetic resonance images co-occur in neurological patients. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
We investigated the nature of the relationship between depression and vascular diseases by reviewing epidemiological, clinical, neuroimaging and neuropathology studies which have reported on the relationship of depression to coronary artery disease, stroke disease, alterations in blood pressure, vascular dementia, diabetes mellitus and cholesterol levels and by reviewing potential mechanisms by which depression could be associated with vascular diseases. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Previous studies have suggested an acutely improving effect of insulin on memory function. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetes mellitus may be associated with an increased risk of developing AD and may affect cognitive systems differentially. 5 key findings →
Design: cohort study Participants: 151 Evidence: moderate
Full summary, score breakdown and related studies → Original source
High homocysteine levels were not associated with AD and were not related to a decrease in memory scores over time. 4 key findings →
Design: longitudinal study Participants: 679 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Employing time-dependent proportional hazards modeling, the authors found no significant association between statin use and incident dementia or probable AD. 2 key findings →
Design: cohort study Participants: 312 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Stroke increases a subject's risk of dementia as compared with age- and sex-matched controls. 3 key findings →
Design: case-control study Participants: 212 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Hyperinsulinemia is associated with a higher risk of AD and decline in memory. 4 key findings →
Participants: 683 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this community-based sample, 3 to 4% of nondemented persons met MCI operational criteria; despite increased risk of progressing to dementia, a substantial proportion also remained stable or reverted to normal during follow-up. 3 key findings →
Participants: 1,248 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We conclude that patients with mild cognitive impairment and depression are at more than twice the risk of developing dementia of Alzheimer type as those without depression. 4 key findings →
Design: cohort study Participants: 114 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
White matter lesions, especially in the periventricular region, increase the risk of dementia in elderly people. 2 key findings →
Design: cohort study Participants: 1,077 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Older age is associated with increased HAD in this HIV-1 cohort. 2 key findings →
Design: cross-sectional Participants: 106 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. 3 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The First Key Symposium was held in Stockholm, Sweden, 2-5 September 2003. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Unlike Alzheimer disease, for which the APOE-epsilon4 allele increases the prevalence and the APOE-epsilon2 allele is protective, the authors' analysis shows the APOE-epsilon2 allele, but not the APOE-epsilon4 allele, to be positively associated with sporadic Parkinson disease. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →